• Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform used by a wide U.S. oncology network.
• The move brings Abbott's advanced cancer diagnostics directly into clinicians' electronic workflows, aiming to simplify ordering and results review.
• This development follows Abbott's expansion into cancer diagnostics through its deal with Exact Sciences.

For investors tracking NYSE:ABT, this news sits against a mixed share price picture. The stock last closed at $101.88, with a 6.4% return over 3 years, a 21.8% decline over 1 year, and a 6.9% decline over 5 years. Over shorter periods, returns have also been weak, with a 2.8% decline over 7 days, 12.4% over 30 days, and 18.0% year to date.

This integration pushes Abbott deeper into precision oncology workflows. It may influence how you think about its position in cancer diagnostics over time. As the OncoEMR rollout progresses, the key things to watch will be clinician adoption of Abbott's tests and any signs that the Exact Sciences transaction is translating into broader use of its oncology portfolio.

Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

This integration gives Abbott a much bigger footprint in precision oncology by placing its tests directly inside the daily software used at more than 1,600 U.S. community cancer centers. Instead of separate portals and manual data entry, clinicians can order assays such as Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard, then see status updates and results inside OncoEMR. For a company that has recently expanded in cancer diagnostics through the Exact Sciences deal, this appears to be a practical way to put that portfolio in front of community oncologists, where most U.S. cancer care occurs. For you as an investor, the key angle is distribution and workflow integration, which can be as important as test performance when it comes to real-world usage.

How This Fits Into The Abbott Laboratories Narrative

• The move supports the existing narrative that Abbott is leaning into long-term disease management by embedding oncology testing alongside its broader diagnostics and chronic care tools.
• It also tests the assumption that Abbott can integrate large acquisitions smoothly, since effective use of the Exact Sciences portfolio now depends partly on how well this EMR connection performs in busy clinics.
• The narrative focuses heavily on diabetes, emerging markets, and device pipelines. It may not fully account for how EMR-integrated oncology diagnostics could influence Abbott’s position versus peers like Roche, Danaher’s Cepheid unit, or Thermo Fisher.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Abbott Laboratories to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Execution risk if clinicians stick with existing testing habits or competing oncology panels from groups such as Roche or Exact Sciences’ former stand-alone channels, which could limit uptake of the integrated workflow.
• ⚠️ Pressure on margins if payers push back on reimbursement or if Abbott needs to price aggressively to compete with established oncology testing providers.
• 🎁 Greater access to more than 4,700 providers in community oncology settings, which could support broader use of Abbott’s precision oncology portfolio if ordering remains simple and reliable.
• 🎁 A more integrated cancer care offering when combined with Abbott’s presence in medical nutrition and diagnostics, which can help the company compete across the full patient journey rather than with single products only.

What To Watch Going Forward

From here, watch how quickly practices in Flatiron’s network adopt ordering of Abbott tests inside OncoEMR, and whether key opinion leaders in oncology highlight workflow or clinical benefits. Any comments from Abbott on test volumes, reimbursement trends, or additional EMR integrations will also matter, as will moves from competitors to secure similar positions in oncology workflows. For investors linking this to the wider Abbott story, the question is whether this integration supports the broader cancer diagnostics platform that came with Exact Sciences and fits alongside Abbott’s other chronic disease franchises.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Abbott Laboratories, head to the community page for Abbott Laboratories to stay informed on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.